Shattuck Labs, Inc. (STTK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 10 | 30 | 1 | 2 | 6 | 1 | 1 | - |
| Operating profit | $m | -52 | -56 | ||||||
| Net profit | $m | -37 | -45 | -102 | -87 | -75 | -49 | -53 | -35 |
| EPS reported | $ | -0.70 | -0.51 | ||||||
| Operating cashflow per share | $ | -0.57 | -0.37 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.57 | -0.37 | ||||||
| Free cash flow | $m | -40 | -41 | ||||||
| Net debt | $m | -76 | -62 | ||||||
| Book value equity | $m | 82 | 211 | ||||||
| Book value per share | $ | 1.18 | 1.63 | ||||||
| Number of shares | m | 69.58 | 129.78 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.08 | 1.20 | ||||||
| P/S LTM | x | 253.99 | 253.99 | ||||||
| P/FCF LTM | x | -6.36 | -6.16 | ||||||
| EV/EBITDA LTM | x | -4.48 | -4.17 | ||||||
| EV/Sales LTM | x | 202.21 | 256.89 | ||||||
| Earnings Yield LTM | % | -19.22% | -6.18% | ||||||
| FCF Yield | % | -15.73% | -16.24% | ||||||
| Quality | |||||||||
| ROE | % | -59.24% | -60.73% | ||||||
| ROIC | % | -60.73% | -53.34% | ||||||
| Operating margin | % | -51.51% | -52.66% | ||||||
| Gross margin | % | -1.95% | -8.44% | ||||||
| FCF/Sales | % | -3995.3% | -4128.2% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -82.52% | -82.52% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -16.50 | -15.42 | ||||||
| Net Debt/EBITDA | x | 1.15 | 1.89 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.62% | +0.59% | ||||||
| Net debt/Equity | x | -0.93 | -0.30 | ||||||
| Gross debt/equity | x | 0.03 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free